Physician profile
Jazila Mantis
NPI 1710082847
$346.95
in general payments reported to CMS, 2019-2025
11 companies · $103 in 2025
The $103 reported for 2025 was less than what a typical Infectious Disease provider received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $52.79 · 2020: $22.83 · 2021: $44.17 · 2022: $51.46 · 2023: $72.39 · 2025: $103.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $176.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $175.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $152.57 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $42.80 | 2019-2020 | |
| Janssen Biotech, INC. | $32.32 | 2025 | Tremfya |
| Glaxosmithkline, LLC. | $24.69 | 2025 | Shingrix |
| Shionogi INC | $22.69 | 2021 | |
| Aurinia Pharma U.S., INC. | $21.48 | 2021 | |
| Merck Sharp & Dohme LLC | $19.44 | 2022 | |
| Gilead Sciences, INC. | $16.74 | 2025 | Veklury |
| Amryt Pharma Holdings LTD | $14.22 | 2022 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jazila Mantis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.